UNSPSC 51343506: Cidofovir anhydrous

This classification denotes an antiviral agent with the molecular formula C8H14N3O6P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 768M1V522C, chemically known as phosphonic acid, ((2-(4-amino-2-oxo-1(2h)-pyrimidinyl)-1-(hydroxymethyl)ethoxy)methyl)-, (s)-, but more generally known as cidofovir anhydrous, which bears US NIH Compound Identifier 60613. European Medicines Agency schedules cidofovir anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06257MIG.

Most nations, for tariff purposes, schedule cidofovir anhydrous under HS 29335995. Cidofovir anhydrous bears US NLM identifiers UMLS ID C2699210 and NCI Concept Code C77925. SMILES: C1CN(C(=O)NC1N)C[C@@H](CO)OCP(=O)(O)O.

UNSPSC 51343506 Cidofovir anhydrous (Commodity) shows minimal alignment between the code's nominal pharmaceutical scope and recent state and local opportunities posted under it. The three substantive opportunities on record involve naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products — none of which are cidofovir or antiviral compounds. A fourth record, Tampa Fire Department medical and first aid supplies, similarly shows no connection to cidofovir. The code appears to see irregular or mistagged solicitation activity, suggesting that state and local procurement offices are either not using this code consistently for cidofovir purchases or are not actively procuring cidofovir through open competitive solicitations at present.

The few opportunities posted under this code involve different issuing bodies and geographies: Seminole County, Florida (naloxone and drug deactivation systems, IFB, due Jul 26, 2023); Texas Health and Human Services Commission (direct-to-manufacturer prescription RFI, due Apr 3, 2026); City of Tampa (medical and first aid supplies, IFB, due Mar 13, 2026, with $700,000 estimated value and SLBE set-aside); and Minnesota Multistate Cooperative Purchasing Alliance (generic pharmaceuticals and OTC products, RFP, due Mar 26, 2026). Activity is scattered across Texas, Florida, and Minnesota without evidence of concentration. Because the code shows no recent opportunities for cidofovir itself and the posted solicitations appear to be mislabeled or unrelated to the commodity's actual scope, pursuit of this code is not advisable until clearer recent demand signals emerge.